246 related articles for article (PubMed ID: 34407972)
1. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract][Full Text] [Related]
2. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
[TBL] [Abstract][Full Text] [Related]
3. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
Deng X; Li X; Guo X; Lu Y; Xie Y; Huang X; Lin J; Tan W; Wang C
Neoplasia; 2022 Jun; 28():100788. PubMed ID: 35378464
[TBL] [Abstract][Full Text] [Related]
6. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
Setten RL; Lightfoot HL; Habib NA; Rossi JJ
Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
[TBL] [Abstract][Full Text] [Related]
7. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
[TBL] [Abstract][Full Text] [Related]
8. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
9. Dual negative roles of C/EBPα in the expansion and pro-tumor functions of MDSCs.
Mackert JR; Qu P; Min Y; Johnson PF; Yang L; Lin PC
Sci Rep; 2017 Oct; 7(1):14048. PubMed ID: 29070836
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Liver Cancer by C/EBPA saRNA.
Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
[TBL] [Abstract][Full Text] [Related]
11. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
[TBL] [Abstract][Full Text] [Related]
12. MiR-486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro.
Jiang J; Gao Q; Gong Y; Huang L; Lin H; Zhou X; Liang X; Guo W
Cancer Med; 2018 Sep; 7(9):4627-4638. PubMed ID: 30073773
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
14. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
[TBL] [Abstract][Full Text] [Related]
17. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
18. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
[TBL] [Abstract][Full Text] [Related]
19. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.
Avellino R; Havermans M; Erpelinck C; Sanders MA; Hoogenboezem R; van de Werken HJ; Rombouts E; van Lom K; van Strien PM; Gebhard C; Rehli M; Pimanda J; Beck D; Erkeland S; Kuiken T; de Looper H; Gröschel S; Touw I; Bindels E; Delwel R
Blood; 2016 Jun; 127(24):2991-3003. PubMed ID: 26966090
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma.
Tan EH; Hooi SC; Laban M; Wong E; Ponniah S; Wee A; Wang ND
Cancer Res; 2005 Nov; 65(22):10330-7. PubMed ID: 16288022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
